Side-by-side comparison of AI visibility scores, market position, and capabilities
Google's YouTube ad-free subscription with background playback and YouTube Music; 100M subscribers growing as anti-ad-blocker enforcement drives conversions from ad-supported viewing.
YouTube Premium is Google's subscription tier for YouTube that removes advertisements from videos, enables background playback (continuing video audio when the screen is off or switching to another app), and provides access to YouTube Music (Google's music streaming service) — offering an ad-free, feature-enhanced YouTube experience for $13.99/month. Part of Google (Alphabet Inc., NASDAQ: GOOGL), YouTube Premium has grown to approximately 100 million subscribers as YouTube's content ecosystem has grown, making it a significant recurring revenue stream alongside YouTube's dominant advertising business.\n\nYouTube Premium's value proposition is primarily ad-free viewing — YouTube's ad load has increased significantly as the platform has expanded advertising, making the ad-free experience increasingly attractive to heavy viewers. Background playback is particularly valued for music and podcast content. YouTube Music inclusion (equivalent to Spotify or Apple Music) adds streaming music at no additional cost, bundling two streaming services in one subscription. YouTube Originals (exclusive content) historically differentiated Premium but Google has largely discontinued new Originals production.\n\nIn 2025, YouTube Premium competes with Spotify and Apple Music for streaming music subscriptions, but its primary competition is against its own free ad-supported tier — YouTube must balance monetizing through Premium subscriptions versus maximizing ad revenue from the much larger free user base. Google has increased enforcement against third-party ad blockers on YouTube in 2023-2024, driving significant Premium subscription growth. YouTube's 2025 strategy focuses on continued anti-ad-blocker measures that push users toward Premium, investing in YouTube TV (live TV streaming service), and growing YouTube Shopping integrations that convert viewer attention into commerce.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.